Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 12/20 | 0.42 |
| ▸ | KLKB1 | P03952 | 4/20 | 0.37 |
| ▸ | F11 | P03951 | 3/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD1 | P21728 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | DRD5 | P21918 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1010379 | 0.90 | GRM5 (0.47) | GRM5MAPTALDH1A1HPGD | |
| SCHEMBL1011101 | 0.89 | DRD1 (0.42) | GRM5KLKB1DRD1ALDH1A1LMNA | |
| SCHEMBL1010062 | 0.88 | GRM5 (0.41) | GRM5KLKB1F11ALDH1A1 | |
| SCHEMBL1011294 | 0.87 | KLKB1 (0.45) | GRM5KLKB1F11ALDH1A1LMNA | |
| SCHEMBL1010093 | 0.87 | DRD1 (0.43) | GRM5KLKB1F11DRD1 | |
| SCHEMBL1011156 | 0.87 | GRM5 (0.41) | GRM5KLKB1F11ALDH1A1LMNA | |
| SCHEMBL1010182 | 0.87 | GRM5 (0.42) | GRM5KLKB1F11 | |
| SCHEMBL1009690 | 0.86 | GRM5 (0.43) | GRM5KLKB1F11ALDH1A1LMNA | |
| SCHEMBL1009118 | 0.86 | GRM5 (0.46) | GRM5DRD1MAPTALDH1A1LMNA | |
| SCHEMBL3816184 | 0.86 | DRD1 (0.38) | GRM5KLKB1F11DRD2DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012139876-A1 | ENTERIC FORMULATIONS OF METABOTROPIC GLUTAMATE RECEPTOR MODULATORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2012-10-18 | — | — | WO | claimed |
| US-20110212956-A1 | Pyrazolopyrimidines for treating CNS disorders | MERZ PHARMA GMBH & CO. KGAA (DE) | 2011-09-01 | — | — | US | claimed |
| US-7985753-B2 | Substituted pyrazolo[1,5-A]pyrimidines as metabotropic glutamate receptor modulators | MERZ PHARMA GMBH & CO. KGAA (DE) | 2011-07-26 | — | — | US | claimed |
| EP-2295439-A1 | Substituted pyrazolopyrimidines, a process for their preparation and their use as medicine | Merz Pharma GmbH & Co. KGaA (DE) | 2011-03-16 | — | — | EP | claimed |
| EP-2054416-B1 | SUBSTITUTED PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | MERZ PHARMA GMBH & CO KGAA (DE) | 2011-01-05 | — | — | EP | claimed |
| US-20080039458-A1 | Substituted pyrazolopyrimidines, a process for their preparation and their use as medicine | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-14 | — | — | US | claimed |
| US-20150165756-A1 | STENCILS | DTG INT GMBH (CH) | 2015-06-18 | — | — | US | disclosed |
| WO-2013087808-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A PYRAZOLOPYRIMIDME AND CYCLODEXTRIN | MERZ PHARMA GMBH & CO. KGAA (DE) | 2013-06-20 | — | — | WO | disclosed |
| WO-2013087815-A1 | LIQUID PHARMACEUTICAL COMPOSITION CONTAINING A PYRAZOLOPYRIMIDINE DERIVATIVE AND PHARMACEUTICAL USES THEREOF | MERZ PHARMA GMBH & CO. KGAA (DE) | 2013-06-20 | — | — | WO | disclosed |
| WO-2012139876-A1 | ENTERIC FORMULATIONS OF METABOTROPIC GLUTAMATE RECEPTOR MODULATORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2012-10-18 | — | — | WO | disclosed |
| US-20110212956-A1 | Pyrazolopyrimidines for treating CNS disorders | MERZ PHARMA GMBH & CO. KGAA (DE) | 2011-09-01 | — | — | US | disclosed |
| US-20110212956-A1 | Pyrazolopyrimidines for treating CNS disorders | MERZ PHARMA GMBH & CO. KGAA (DE) | 2011-09-01 | — | — | US | disclosed |
| US-20110212956-A1 | Pyrazolopyrimidines for treating CNS disorders | MERZ PHARMA GMBH & CO. KGAA (DE) | 2011-09-01 | — | — | US | disclosed |
| EP-2295439-A1 | Substituted pyrazolopyrimidines, a process for their preparation and their use as medicine | Merz Pharma GmbH & Co. KGaA (DE) | 2011-03-16 | — | — | EP | disclosed |
| EP-2295439-A1 | Substituted pyrazolopyrimidines, a process for their preparation and their use as medicine | Merz Pharma GmbH & Co. KGaA (DE) | 2011-03-16 | — | — | EP | disclosed |
| EP-2054416-B1 | SUBSTITUTED PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | MERZ PHARMA GMBH & CO KGAA (DE) | 2011-01-05 | — | — | EP | disclosed |
| US-20080039458-A1 | Substituted pyrazolopyrimidines, a process for their preparation and their use as medicine | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-14 | — | — | US | disclosed |
| US-20080039458-A1 | Substituted pyrazolopyrimidines, a process for their preparation and their use as medicine | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-14 | — | — | US | disclosed |
| US-20080039458-A1 | Substituted pyrazolopyrimidines, a process for their preparation and their use as medicine | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-14 | — | — | US | disclosed |
| WO-2008015269-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212956-A1 | Pyrazolopyrimidines for treating CNS disorders | GRM5, GRM3, GRM1 | GRM5 1/4885KLKB1 3986/4885F11 2493/4885 |
| US-20080039458-A1 | Substituted pyrazolopyrimidines, a process for their preparation and their use as medicine | GRM5, GRM1, GRM3 | GRM5 1/4885KLKB1 4205/4885F11 2112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.